SCHEMBL731615

SCHEMBL731615

CS(=O)(=O)O[C@H]1CCN(C(=O)OCc2ccc3ccccc3c2)C[C@H]1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F13A1 P00488 1/20 0.43
TGM2 P21980 1/20 0.43
TGM1 P22735 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.39
CYP2C19 P33261 1/20 0.39
BCL9 O00512 2/20 0.38
CTNNB1 P35222 2/20 0.38
PDE4B Q07343 1/20 0.37
REN P00797 1/20 0.37
MMP1 P03956 1/20 0.37
MMP3 P08254 1/20 0.37
MMP7 P09237 1/20 0.37
MMP9 P14780 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL730005 1.00 F13A1 (0.43) F13A1TGM2TGM1SMN1; SMN2NPC1
SCHEMBL731032 1.00 F13A1 (0.43) F13A1TGM2TGM1SMN1; SMN2NPC1
SCHEMBL2166686 0.88 SMN1; SMN2 (0.53) F13A1TGM2TGM1SMN1; SMN2NPC1
SCHEMBL2166676 0.88 SMN1; SMN2 (0.53) F13A1TGM2TGM1SMN1; SMN2NPC1
SCHEMBL2166680 0.88 SMN1; SMN2 (0.53) F13A1TGM2TGM1SMN1; SMN2NPC1
SCHEMBL729096 0.82 SMN1; SMN2 (0.45) F13A1TGM2TGM1SMN1; SMN2NPC1
SCHEMBL729892 0.82 SMN1; SMN2 (0.45) F13A1TGM2TGM1SMN1; SMN2NPC1
SCHEMBL729095 0.82 SMN1; SMN2 (0.45) F13A1TGM2TGM1SMN1; SMN2NPC1
SCHEMBL30325540 0.79 SMN1; SMN2 (0.53) F13A1TGM2TGM1SMN1; SMN2NPC1
SCHEMBL376043 0.79 SMN1; SMN2 (0.53) F13A1TGM2TGM1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137184-B1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2013-05-08 EP disclosed
US-8138181-B2 Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2012-03-20 US disclosed
US-20100029633-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029633-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS PIM1, PIM3, PIM2 F13A1 1765/4885TGM2 4536/4885TGM1 3556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.